Dosage adjustment from simple nortriptyline spot level predictor tests in depressed patients

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Therapeutics

Background:

• Endogenous depression treatment often involves nortriptyline.
• Monitoring plasma concentrations of antidepressants is crucial for optimizing efficacy and minimizing toxicity.
• Establishing reliable methods for therapeutic drug monitoring is essential in clinical practice.

Purpose of the Study:

• To investigate the relationship between plasma nortriptyline concentrations and therapeutic outcomes in patients with endogenous depression.
• To evaluate the utility of early plasma nortriptyline concentrations as predictors of steady-state levels and treatment response.
• To propose a simplified monitoring test for clinical use.

Main Methods:

• Kinetic and 4-week treatment study involving 20 patients with endogenous depression.
• Measurement of plasma nortriptyline concentrations at various time points (24, 48, 72 hours, and steady-state).
• Assessment of depression amelioration using the Hamilton Rating Scale (HRS).

Main Results:

• Steady-state plasma nortriptyline concentrations above 200 microgram/L were significantly associated with poorer therapeutic outcomes.
• High correlations were observed between 24, 48, and 72-hour concentrations and steady-state concentrations (r = 0.81–0.97).
• Significant correlations were found between early plasma concentrations (24, 48, 72 hours) and depression amelioration (Rs = 0.74–0.79), unlike nortriptyline half-life (Rs = 0.33).

Conclusions:

• A single 48-hour plasma nortriptyline concentration is a reliable and simplified monitoring test for clinical settings.
• This test aids in dosage adjustment to maximize antidepressant effects and minimize toxicity.
• A tentative dosage adjustment schedule based on 24 or 48-hour plasma concentrations is proposed for individualized nortriptyline treatment.